nodes	percent_of_prediction	percent_of_DWPC	metapath
Arformoterol—CYP2A6—Methoxsalen—hematologic cancer	0.065	0.104	CbGbCtD
Arformoterol—CYP2A6—Ifosfamide—hematologic cancer	0.0474	0.0756	CbGbCtD
Arformoterol—CYP2C9—Bexarotene—hematologic cancer	0.0347	0.0553	CbGbCtD
Arformoterol—CYP2A6—Prednisolone—hematologic cancer	0.0316	0.0504	CbGbCtD
Arformoterol—CYP2D6—Lomustine—hematologic cancer	0.0295	0.047	CbGbCtD
Arformoterol—CYP2C9—Idarubicin—hematologic cancer	0.0288	0.0458	CbGbCtD
Arformoterol—CYP2D6—Idarubicin—hematologic cancer	0.0263	0.0419	CbGbCtD
Arformoterol—CYP2C19—Bortezomib—hematologic cancer	0.0256	0.0408	CbGbCtD
Arformoterol—CYP2D6—Hydroxyurea—hematologic cancer	0.0224	0.0356	CbGbCtD
Arformoterol—CYP2C19—Thalidomide—hematologic cancer	0.0223	0.0355	CbGbCtD
Arformoterol—CYP2C9—Bortezomib—hematologic cancer	0.0213	0.0339	CbGbCtD
Arformoterol—CYP2C19—Teniposide—hematologic cancer	0.0213	0.0339	CbGbCtD
Arformoterol—CYP2C19—Ifosfamide—hematologic cancer	0.0196	0.0313	CbGbCtD
Arformoterol—CYP2D6—Bortezomib—hematologic cancer	0.0194	0.031	CbGbCtD
Arformoterol—CYP2C19—Imatinib—hematologic cancer	0.0187	0.0299	CbGbCtD
Arformoterol—CYP2A6—Dexamethasone—hematologic cancer	0.0186	0.0297	CbGbCtD
Arformoterol—CYP2C9—Thalidomide—hematologic cancer	0.0185	0.0295	CbGbCtD
Arformoterol—CYP2C9—Teniposide—hematologic cancer	0.0177	0.0282	CbGbCtD
Arformoterol—CYP2C9—Ifosfamide—hematologic cancer	0.0163	0.026	CbGbCtD
Arformoterol—CYP2C9—Imatinib—hematologic cancer	0.0156	0.0248	CbGbCtD
Arformoterol—CYP2D6—Imatinib—hematologic cancer	0.0142	0.0227	CbGbCtD
Arformoterol—CYP2C9—Nilotinib—hematologic cancer	0.0142	0.0226	CbGbCtD
Arformoterol—CYP2D6—Nilotinib—hematologic cancer	0.0129	0.0206	CbGbCtD
Arformoterol—CYP2D6—Vinorelbine—hematologic cancer	0.0128	0.0205	CbGbCtD
Arformoterol—CYP2C19—Prednisone—hematologic cancer	0.0123	0.0197	CbGbCtD
Arformoterol—CYP2C9—Cisplatin—hematologic cancer	0.00793	0.0126	CbGbCtD
Arformoterol—CYP2D6—Vinblastine—hematologic cancer	0.00791	0.0126	CbGbCtD
Arformoterol—CYP2C19—Dexamethasone—hematologic cancer	0.00771	0.0123	CbGbCtD
Arformoterol—CYP2C9—Dexamethasone—hematologic cancer	0.00641	0.0102	CbGbCtD
Arformoterol—CYP2D6—Dexamethasone—hematologic cancer	0.00586	0.00934	CbGbCtD
Arformoterol—CYP2D6—Doxorubicin—hematologic cancer	0.00486	0.00775	CbGbCtD
Arformoterol—Isoprenaline—PIK3R1—hematologic cancer	0.00238	1	CrCbGaD
Arformoterol—Cardiac disorder—Epirubicin—hematologic cancer	3.59e-05	0.00011	CcSEcCtD
Arformoterol—Rhinitis—Doxorubicin—hematologic cancer	3.59e-05	0.000109	CcSEcCtD
Arformoterol—Hypersensitivity—Prednisolone—hematologic cancer	3.56e-05	0.000109	CcSEcCtD
Arformoterol—Pharyngitis—Doxorubicin—hematologic cancer	3.55e-05	0.000108	CcSEcCtD
Arformoterol—Dyspepsia—Dexamethasone—hematologic cancer	3.55e-05	0.000108	CcSEcCtD
Arformoterol—Dyspepsia—Betamethasone—hematologic cancer	3.55e-05	0.000108	CcSEcCtD
Arformoterol—Urinary tract disorder—Doxorubicin—hematologic cancer	3.53e-05	0.000108	CcSEcCtD
Arformoterol—Urticaria—Triamcinolone—hematologic cancer	3.53e-05	0.000108	CcSEcCtD
Arformoterol—Oedema peripheral—Doxorubicin—hematologic cancer	3.53e-05	0.000108	CcSEcCtD
Arformoterol—Dysgeusia—Methotrexate—hematologic cancer	3.52e-05	0.000108	CcSEcCtD
Arformoterol—Asthenia—Etoposide—hematologic cancer	3.52e-05	0.000107	CcSEcCtD
Arformoterol—Connective tissue disorder—Doxorubicin—hematologic cancer	3.52e-05	0.000107	CcSEcCtD
Arformoterol—Body temperature increased—Triamcinolone—hematologic cancer	3.52e-05	0.000107	CcSEcCtD
Arformoterol—Oedema—Prednisone—hematologic cancer	3.51e-05	0.000107	CcSEcCtD
Arformoterol—Anaphylactic shock—Prednisone—hematologic cancer	3.51e-05	0.000107	CcSEcCtD
Arformoterol—Urethral disorder—Doxorubicin—hematologic cancer	3.51e-05	0.000107	CcSEcCtD
Arformoterol—Nausea—Mitoxantrone—hematologic cancer	3.5e-05	0.000107	CcSEcCtD
Arformoterol—Nausea—Irinotecan—hematologic cancer	3.5e-05	0.000107	CcSEcCtD
Arformoterol—Immune system disorder—Epirubicin—hematologic cancer	3.49e-05	0.000107	CcSEcCtD
Arformoterol—Infection—Prednisone—hematologic cancer	3.49e-05	0.000107	CcSEcCtD
Arformoterol—Mediastinal disorder—Epirubicin—hematologic cancer	3.49e-05	0.000106	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Betamethasone—hematologic cancer	3.48e-05	0.000106	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Dexamethasone—hematologic cancer	3.48e-05	0.000106	CcSEcCtD
Arformoterol—Back pain—Methotrexate—hematologic cancer	3.48e-05	0.000106	CcSEcCtD
Arformoterol—Fatigue—Betamethasone—hematologic cancer	3.48e-05	0.000106	CcSEcCtD
Arformoterol—Fatigue—Dexamethasone—hematologic cancer	3.48e-05	0.000106	CcSEcCtD
Arformoterol—Pruritus—Etoposide—hematologic cancer	3.47e-05	0.000106	CcSEcCtD
Arformoterol—Arrhythmia—Epirubicin—hematologic cancer	3.46e-05	0.000105	CcSEcCtD
Arformoterol—Pain—Betamethasone—hematologic cancer	3.45e-05	0.000105	CcSEcCtD
Arformoterol—Pain—Dexamethasone—hematologic cancer	3.45e-05	0.000105	CcSEcCtD
Arformoterol—Visual impairment—Doxorubicin—hematologic cancer	3.45e-05	0.000105	CcSEcCtD
Arformoterol—Nervous system disorder—Prednisone—hematologic cancer	3.45e-05	0.000105	CcSEcCtD
Arformoterol—Tachycardia—Prednisone—hematologic cancer	3.43e-05	0.000105	CcSEcCtD
Arformoterol—Skin disorder—Prednisone—hematologic cancer	3.41e-05	0.000104	CcSEcCtD
Arformoterol—Nausea—Gemcitabine—hematologic cancer	3.41e-05	0.000104	CcSEcCtD
Arformoterol—Vomiting—Cisplatin—hematologic cancer	3.4e-05	0.000104	CcSEcCtD
Arformoterol—Mental disorder—Epirubicin—hematologic cancer	3.39e-05	0.000103	CcSEcCtD
Arformoterol—Rash—Cisplatin—hematologic cancer	3.37e-05	0.000103	CcSEcCtD
Arformoterol—Dermatitis—Cisplatin—hematologic cancer	3.37e-05	0.000103	CcSEcCtD
Arformoterol—Malnutrition—Epirubicin—hematologic cancer	3.37e-05	0.000103	CcSEcCtD
Arformoterol—Diarrhoea—Etoposide—hematologic cancer	3.35e-05	0.000102	CcSEcCtD
Arformoterol—Ill-defined disorder—Methotrexate—hematologic cancer	3.34e-05	0.000102	CcSEcCtD
Arformoterol—Feeling abnormal—Dexamethasone—hematologic cancer	3.32e-05	0.000101	CcSEcCtD
Arformoterol—Feeling abnormal—Betamethasone—hematologic cancer	3.32e-05	0.000101	CcSEcCtD
Arformoterol—Cardiac disorder—Doxorubicin—hematologic cancer	3.32e-05	0.000101	CcSEcCtD
Arformoterol—Tension—Epirubicin—hematologic cancer	3.3e-05	0.000101	CcSEcCtD
Arformoterol—Gastrointestinal pain—Dexamethasone—hematologic cancer	3.3e-05	0.000101	CcSEcCtD
Arformoterol—Gastrointestinal pain—Betamethasone—hematologic cancer	3.3e-05	0.000101	CcSEcCtD
Arformoterol—Dysgeusia—Epirubicin—hematologic cancer	3.3e-05	0.000101	CcSEcCtD
Arformoterol—Hypersensitivity—Triamcinolone—hematologic cancer	3.28e-05	0.0001	CcSEcCtD
Arformoterol—Nervousness—Epirubicin—hematologic cancer	3.27e-05	9.98e-05	CcSEcCtD
Arformoterol—Back pain—Epirubicin—hematologic cancer	3.26e-05	9.94e-05	CcSEcCtD
Arformoterol—Malaise—Methotrexate—hematologic cancer	3.24e-05	9.9e-05	CcSEcCtD
Arformoterol—Dizziness—Etoposide—hematologic cancer	3.24e-05	9.89e-05	CcSEcCtD
Arformoterol—Muscle spasms—Epirubicin—hematologic cancer	3.24e-05	9.88e-05	CcSEcCtD
Arformoterol—Immune system disorder—Doxorubicin—hematologic cancer	3.23e-05	9.86e-05	CcSEcCtD
Arformoterol—Mediastinal disorder—Doxorubicin—hematologic cancer	3.23e-05	9.84e-05	CcSEcCtD
Arformoterol—Urticaria—Betamethasone—hematologic cancer	3.21e-05	9.78e-05	CcSEcCtD
Arformoterol—Urticaria—Dexamethasone—hematologic cancer	3.21e-05	9.78e-05	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Prednisone—hematologic cancer	3.2e-05	9.77e-05	CcSEcCtD
Arformoterol—Dizziness—Prednisolone—hematologic cancer	3.2e-05	9.76e-05	CcSEcCtD
Arformoterol—Arrhythmia—Doxorubicin—hematologic cancer	3.2e-05	9.76e-05	CcSEcCtD
Arformoterol—Asthenia—Triamcinolone—hematologic cancer	3.19e-05	9.73e-05	CcSEcCtD
Arformoterol—Body temperature increased—Betamethasone—hematologic cancer	3.19e-05	9.73e-05	CcSEcCtD
Arformoterol—Abdominal pain—Dexamethasone—hematologic cancer	3.19e-05	9.73e-05	CcSEcCtD
Arformoterol—Abdominal pain—Betamethasone—hematologic cancer	3.19e-05	9.73e-05	CcSEcCtD
Arformoterol—Body temperature increased—Dexamethasone—hematologic cancer	3.19e-05	9.73e-05	CcSEcCtD
Arformoterol—Nausea—Cisplatin—hematologic cancer	3.18e-05	9.7e-05	CcSEcCtD
Arformoterol—Insomnia—Prednisone—hematologic cancer	3.18e-05	9.7e-05	CcSEcCtD
Arformoterol—Pruritus—Triamcinolone—hematologic cancer	3.15e-05	9.6e-05	CcSEcCtD
Arformoterol—Cough—Methotrexate—hematologic cancer	3.14e-05	9.58e-05	CcSEcCtD
Arformoterol—Mental disorder—Doxorubicin—hematologic cancer	3.14e-05	9.57e-05	CcSEcCtD
Arformoterol—Ill-defined disorder—Epirubicin—hematologic cancer	3.12e-05	9.53e-05	CcSEcCtD
Arformoterol—Vomiting—Etoposide—hematologic cancer	3.12e-05	9.51e-05	CcSEcCtD
Arformoterol—Malnutrition—Doxorubicin—hematologic cancer	3.12e-05	9.51e-05	CcSEcCtD
Arformoterol—Agitation—Epirubicin—hematologic cancer	3.09e-05	9.44e-05	CcSEcCtD
Arformoterol—Dyspepsia—Prednisone—hematologic cancer	3.09e-05	9.44e-05	CcSEcCtD
Arformoterol—Rash—Etoposide—hematologic cancer	3.09e-05	9.43e-05	CcSEcCtD
Arformoterol—Dermatitis—Etoposide—hematologic cancer	3.09e-05	9.42e-05	CcSEcCtD
Arformoterol—Headache—Etoposide—hematologic cancer	3.07e-05	9.37e-05	CcSEcCtD
Arformoterol—Arthralgia—Methotrexate—hematologic cancer	3.06e-05	9.35e-05	CcSEcCtD
Arformoterol—Myalgia—Methotrexate—hematologic cancer	3.06e-05	9.35e-05	CcSEcCtD
Arformoterol—Chest pain—Methotrexate—hematologic cancer	3.06e-05	9.35e-05	CcSEcCtD
Arformoterol—Tension—Doxorubicin—hematologic cancer	3.06e-05	9.33e-05	CcSEcCtD
Arformoterol—Dysgeusia—Doxorubicin—hematologic cancer	3.05e-05	9.31e-05	CcSEcCtD
Arformoterol—Rash—Prednisolone—hematologic cancer	3.05e-05	9.3e-05	CcSEcCtD
Arformoterol—Dermatitis—Prednisolone—hematologic cancer	3.05e-05	9.29e-05	CcSEcCtD
Arformoterol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	3.04e-05	9.28e-05	CcSEcCtD
Arformoterol—Malaise—Epirubicin—hematologic cancer	3.04e-05	9.27e-05	CcSEcCtD
Arformoterol—Fatigue—Prednisone—hematologic cancer	3.03e-05	9.24e-05	CcSEcCtD
Arformoterol—Headache—Prednisolone—hematologic cancer	3.03e-05	9.24e-05	CcSEcCtD
Arformoterol—Discomfort—Methotrexate—hematologic cancer	3.03e-05	9.23e-05	CcSEcCtD
Arformoterol—Nervousness—Doxorubicin—hematologic cancer	3.03e-05	9.23e-05	CcSEcCtD
Arformoterol—Back pain—Doxorubicin—hematologic cancer	3.01e-05	9.2e-05	CcSEcCtD
Arformoterol—Constipation—Prednisone—hematologic cancer	3e-05	9.17e-05	CcSEcCtD
Arformoterol—Muscle spasms—Doxorubicin—hematologic cancer	3e-05	9.14e-05	CcSEcCtD
Arformoterol—Palpitations—Epirubicin—hematologic cancer	2.98e-05	9.08e-05	CcSEcCtD
Arformoterol—Dizziness—Triamcinolone—hematologic cancer	2.94e-05	8.97e-05	CcSEcCtD
Arformoterol—Cough—Epirubicin—hematologic cancer	2.94e-05	8.97e-05	CcSEcCtD
Arformoterol—Anaphylactic shock—Methotrexate—hematologic cancer	2.94e-05	8.96e-05	CcSEcCtD
Arformoterol—Infection—Methotrexate—hematologic cancer	2.92e-05	8.9e-05	CcSEcCtD
Arformoterol—Nausea—Etoposide—hematologic cancer	2.91e-05	8.89e-05	CcSEcCtD
Arformoterol—Hypertension—Epirubicin—hematologic cancer	2.91e-05	8.87e-05	CcSEcCtD
Arformoterol—Feeling abnormal—Prednisone—hematologic cancer	2.9e-05	8.83e-05	CcSEcCtD
Arformoterol—Asthenia—Betamethasone—hematologic cancer	2.89e-05	8.83e-05	CcSEcCtD
Arformoterol—Asthenia—Dexamethasone—hematologic cancer	2.89e-05	8.83e-05	CcSEcCtD
Arformoterol—Ill-defined disorder—Doxorubicin—hematologic cancer	2.89e-05	8.82e-05	CcSEcCtD
Arformoterol—Nervous system disorder—Methotrexate—hematologic cancer	2.88e-05	8.79e-05	CcSEcCtD
Arformoterol—Gastrointestinal pain—Prednisone—hematologic cancer	2.87e-05	8.77e-05	CcSEcCtD
Arformoterol—Nausea—Prednisolone—hematologic cancer	2.87e-05	8.76e-05	CcSEcCtD
Arformoterol—Chest pain—Epirubicin—hematologic cancer	2.87e-05	8.75e-05	CcSEcCtD
Arformoterol—Arthralgia—Epirubicin—hematologic cancer	2.87e-05	8.75e-05	CcSEcCtD
Arformoterol—Myalgia—Epirubicin—hematologic cancer	2.87e-05	8.75e-05	CcSEcCtD
Arformoterol—Agitation—Doxorubicin—hematologic cancer	2.86e-05	8.74e-05	CcSEcCtD
Arformoterol—Anxiety—Epirubicin—hematologic cancer	2.86e-05	8.72e-05	CcSEcCtD
Arformoterol—Pruritus—Betamethasone—hematologic cancer	2.85e-05	8.71e-05	CcSEcCtD
Arformoterol—Pruritus—Dexamethasone—hematologic cancer	2.85e-05	8.71e-05	CcSEcCtD
Arformoterol—Skin disorder—Methotrexate—hematologic cancer	2.85e-05	8.7e-05	CcSEcCtD
Arformoterol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	2.85e-05	8.69e-05	CcSEcCtD
Arformoterol—Discomfort—Epirubicin—hematologic cancer	2.83e-05	8.64e-05	CcSEcCtD
Arformoterol—Vomiting—Triamcinolone—hematologic cancer	2.83e-05	8.63e-05	CcSEcCtD
Arformoterol—Malaise—Doxorubicin—hematologic cancer	2.81e-05	8.57e-05	CcSEcCtD
Arformoterol—Rash—Triamcinolone—hematologic cancer	2.8e-05	8.55e-05	CcSEcCtD
Arformoterol—Dry mouth—Epirubicin—hematologic cancer	2.8e-05	8.55e-05	CcSEcCtD
Arformoterol—Dermatitis—Triamcinolone—hematologic cancer	2.8e-05	8.55e-05	CcSEcCtD
Arformoterol—Urticaria—Prednisone—hematologic cancer	2.79e-05	8.52e-05	CcSEcCtD
Arformoterol—Headache—Triamcinolone—hematologic cancer	2.79e-05	8.5e-05	CcSEcCtD
Arformoterol—Abdominal pain—Prednisone—hematologic cancer	2.78e-05	8.48e-05	CcSEcCtD
Arformoterol—Body temperature increased—Prednisone—hematologic cancer	2.78e-05	8.48e-05	CcSEcCtD
Arformoterol—Diarrhoea—Dexamethasone—hematologic cancer	2.76e-05	8.42e-05	CcSEcCtD
Arformoterol—Diarrhoea—Betamethasone—hematologic cancer	2.76e-05	8.42e-05	CcSEcCtD
Arformoterol—Palpitations—Doxorubicin—hematologic cancer	2.75e-05	8.4e-05	CcSEcCtD
Arformoterol—Oedema—Epirubicin—hematologic cancer	2.75e-05	8.39e-05	CcSEcCtD
Arformoterol—Anaphylactic shock—Epirubicin—hematologic cancer	2.75e-05	8.39e-05	CcSEcCtD
Arformoterol—Hypotension—Methotrexate—hematologic cancer	2.74e-05	8.37e-05	CcSEcCtD
Arformoterol—Infection—Epirubicin—hematologic cancer	2.73e-05	8.33e-05	CcSEcCtD
Arformoterol—Cough—Doxorubicin—hematologic cancer	2.72e-05	8.3e-05	CcSEcCtD
Arformoterol—Nervous system disorder—Epirubicin—hematologic cancer	2.69e-05	8.22e-05	CcSEcCtD
Arformoterol—Hypertension—Doxorubicin—hematologic cancer	2.69e-05	8.21e-05	CcSEcCtD
Arformoterol—Tachycardia—Epirubicin—hematologic cancer	2.68e-05	8.18e-05	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Methotrexate—hematologic cancer	2.68e-05	8.16e-05	CcSEcCtD
Arformoterol—Skin disorder—Epirubicin—hematologic cancer	2.67e-05	8.14e-05	CcSEcCtD
Arformoterol—Dizziness—Betamethasone—hematologic cancer	2.67e-05	8.14e-05	CcSEcCtD
Arformoterol—Dizziness—Dexamethasone—hematologic cancer	2.67e-05	8.14e-05	CcSEcCtD
Arformoterol—Insomnia—Methotrexate—hematologic cancer	2.66e-05	8.1e-05	CcSEcCtD
Arformoterol—Myalgia—Doxorubicin—hematologic cancer	2.65e-05	8.09e-05	CcSEcCtD
Arformoterol—Chest pain—Doxorubicin—hematologic cancer	2.65e-05	8.09e-05	CcSEcCtD
Arformoterol—Arthralgia—Doxorubicin—hematologic cancer	2.65e-05	8.09e-05	CcSEcCtD
Arformoterol—Anxiety—Doxorubicin—hematologic cancer	2.64e-05	8.07e-05	CcSEcCtD
Arformoterol—Nausea—Triamcinolone—hematologic cancer	2.64e-05	8.06e-05	CcSEcCtD
Arformoterol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	2.63e-05	8.04e-05	CcSEcCtD
Arformoterol—Discomfort—Doxorubicin—hematologic cancer	2.62e-05	8e-05	CcSEcCtD
Arformoterol—Dyspnoea—Methotrexate—hematologic cancer	2.62e-05	7.99e-05	CcSEcCtD
Arformoterol—Somnolence—Methotrexate—hematologic cancer	2.61e-05	7.97e-05	CcSEcCtD
Arformoterol—Dry mouth—Doxorubicin—hematologic cancer	2.59e-05	7.92e-05	CcSEcCtD
Arformoterol—Hypersensitivity—Prednisone—hematologic cancer	2.59e-05	7.9e-05	CcSEcCtD
Arformoterol—Dyspepsia—Methotrexate—hematologic cancer	2.58e-05	7.89e-05	CcSEcCtD
Arformoterol—Hypotension—Epirubicin—hematologic cancer	2.57e-05	7.84e-05	CcSEcCtD
Arformoterol—Vomiting—Betamethasone—hematologic cancer	2.57e-05	7.83e-05	CcSEcCtD
Arformoterol—Vomiting—Dexamethasone—hematologic cancer	2.57e-05	7.83e-05	CcSEcCtD
Arformoterol—Rash—Betamethasone—hematologic cancer	2.54e-05	7.76e-05	CcSEcCtD
Arformoterol—Rash—Dexamethasone—hematologic cancer	2.54e-05	7.76e-05	CcSEcCtD
Arformoterol—Anaphylactic shock—Doxorubicin—hematologic cancer	2.54e-05	7.76e-05	CcSEcCtD
Arformoterol—Oedema—Doxorubicin—hematologic cancer	2.54e-05	7.76e-05	CcSEcCtD
Arformoterol—Dermatitis—Dexamethasone—hematologic cancer	2.54e-05	7.76e-05	CcSEcCtD
Arformoterol—Dermatitis—Betamethasone—hematologic cancer	2.54e-05	7.76e-05	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Methotrexate—hematologic cancer	2.54e-05	7.74e-05	CcSEcCtD
Arformoterol—Fatigue—Methotrexate—hematologic cancer	2.53e-05	7.72e-05	CcSEcCtD
Arformoterol—Headache—Betamethasone—hematologic cancer	2.53e-05	7.71e-05	CcSEcCtD
Arformoterol—Headache—Dexamethasone—hematologic cancer	2.53e-05	7.71e-05	CcSEcCtD
Arformoterol—Infection—Doxorubicin—hematologic cancer	2.53e-05	7.71e-05	CcSEcCtD
Arformoterol—Asthenia—Prednisone—hematologic cancer	2.52e-05	7.69e-05	CcSEcCtD
Arformoterol—Pain—Methotrexate—hematologic cancer	2.51e-05	7.66e-05	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Epirubicin—hematologic cancer	2.5e-05	7.64e-05	CcSEcCtD
Arformoterol—Nervous system disorder—Doxorubicin—hematologic cancer	2.49e-05	7.61e-05	CcSEcCtD
Arformoterol—Pruritus—Prednisone—hematologic cancer	2.49e-05	7.59e-05	CcSEcCtD
Arformoterol—Insomnia—Epirubicin—hematologic cancer	2.49e-05	7.58e-05	CcSEcCtD
Arformoterol—Tachycardia—Doxorubicin—hematologic cancer	2.48e-05	7.57e-05	CcSEcCtD
Arformoterol—Skin disorder—Doxorubicin—hematologic cancer	2.47e-05	7.54e-05	CcSEcCtD
Arformoterol—Dyspnoea—Epirubicin—hematologic cancer	2.45e-05	7.48e-05	CcSEcCtD
Arformoterol—Somnolence—Epirubicin—hematologic cancer	2.44e-05	7.45e-05	CcSEcCtD
Arformoterol—Feeling abnormal—Methotrexate—hematologic cancer	2.42e-05	7.38e-05	CcSEcCtD
Arformoterol—Dyspepsia—Epirubicin—hematologic cancer	2.42e-05	7.38e-05	CcSEcCtD
Arformoterol—Diarrhoea—Prednisone—hematologic cancer	2.4e-05	7.34e-05	CcSEcCtD
Arformoterol—Gastrointestinal pain—Methotrexate—hematologic cancer	2.4e-05	7.33e-05	CcSEcCtD
Arformoterol—Nausea—Betamethasone—hematologic cancer	2.4e-05	7.31e-05	CcSEcCtD
Arformoterol—Nausea—Dexamethasone—hematologic cancer	2.4e-05	7.31e-05	CcSEcCtD
Arformoterol—Hypotension—Doxorubicin—hematologic cancer	2.38e-05	7.25e-05	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Epirubicin—hematologic cancer	2.37e-05	7.24e-05	CcSEcCtD
Arformoterol—Fatigue—Epirubicin—hematologic cancer	2.37e-05	7.23e-05	CcSEcCtD
Arformoterol—Pain—Epirubicin—hematologic cancer	2.35e-05	7.17e-05	CcSEcCtD
Arformoterol—Constipation—Epirubicin—hematologic cancer	2.35e-05	7.17e-05	CcSEcCtD
Arformoterol—Urticaria—Methotrexate—hematologic cancer	2.33e-05	7.12e-05	CcSEcCtD
Arformoterol—Dizziness—Prednisone—hematologic cancer	2.32e-05	7.09e-05	CcSEcCtD
Arformoterol—Abdominal pain—Methotrexate—hematologic cancer	2.32e-05	7.08e-05	CcSEcCtD
Arformoterol—Body temperature increased—Methotrexate—hematologic cancer	2.32e-05	7.08e-05	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	2.32e-05	7.07e-05	CcSEcCtD
Arformoterol—Insomnia—Doxorubicin—hematologic cancer	2.3e-05	7.02e-05	CcSEcCtD
Arformoterol—Dyspnoea—Doxorubicin—hematologic cancer	2.27e-05	6.92e-05	CcSEcCtD
Arformoterol—Feeling abnormal—Epirubicin—hematologic cancer	2.26e-05	6.91e-05	CcSEcCtD
Arformoterol—Somnolence—Doxorubicin—hematologic cancer	2.26e-05	6.9e-05	CcSEcCtD
Arformoterol—Gastrointestinal pain—Epirubicin—hematologic cancer	2.25e-05	6.86e-05	CcSEcCtD
Arformoterol—Dyspepsia—Doxorubicin—hematologic cancer	2.24e-05	6.83e-05	CcSEcCtD
Arformoterol—Vomiting—Prednisone—hematologic cancer	2.23e-05	6.82e-05	CcSEcCtD
Arformoterol—Rash—Prednisone—hematologic cancer	2.22e-05	6.76e-05	CcSEcCtD
Arformoterol—Dermatitis—Prednisone—hematologic cancer	2.21e-05	6.75e-05	CcSEcCtD
Arformoterol—Headache—Prednisone—hematologic cancer	2.2e-05	6.72e-05	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Doxorubicin—hematologic cancer	2.2e-05	6.7e-05	CcSEcCtD
Arformoterol—Fatigue—Doxorubicin—hematologic cancer	2.19e-05	6.69e-05	CcSEcCtD
Arformoterol—Urticaria—Epirubicin—hematologic cancer	2.18e-05	6.66e-05	CcSEcCtD
Arformoterol—Constipation—Doxorubicin—hematologic cancer	2.17e-05	6.63e-05	CcSEcCtD
Arformoterol—Pain—Doxorubicin—hematologic cancer	2.17e-05	6.63e-05	CcSEcCtD
Arformoterol—Body temperature increased—Epirubicin—hematologic cancer	2.17e-05	6.63e-05	CcSEcCtD
Arformoterol—Abdominal pain—Epirubicin—hematologic cancer	2.17e-05	6.63e-05	CcSEcCtD
Arformoterol—Hypersensitivity—Methotrexate—hematologic cancer	2.16e-05	6.6e-05	CcSEcCtD
Arformoterol—Asthenia—Methotrexate—hematologic cancer	2.11e-05	6.43e-05	CcSEcCtD
Arformoterol—Feeling abnormal—Doxorubicin—hematologic cancer	2.1e-05	6.39e-05	CcSEcCtD
Arformoterol—Nausea—Prednisone—hematologic cancer	2.09e-05	6.37e-05	CcSEcCtD
Arformoterol—Gastrointestinal pain—Doxorubicin—hematologic cancer	2.08e-05	6.34e-05	CcSEcCtD
Arformoterol—Pruritus—Methotrexate—hematologic cancer	2.08e-05	6.34e-05	CcSEcCtD
Arformoterol—Hypersensitivity—Epirubicin—hematologic cancer	2.02e-05	6.18e-05	CcSEcCtD
Arformoterol—Urticaria—Doxorubicin—hematologic cancer	2.02e-05	6.16e-05	CcSEcCtD
Arformoterol—Body temperature increased—Doxorubicin—hematologic cancer	2.01e-05	6.13e-05	CcSEcCtD
Arformoterol—Abdominal pain—Doxorubicin—hematologic cancer	2.01e-05	6.13e-05	CcSEcCtD
Arformoterol—Diarrhoea—Methotrexate—hematologic cancer	2.01e-05	6.13e-05	CcSEcCtD
Arformoterol—Asthenia—Epirubicin—hematologic cancer	1.97e-05	6.02e-05	CcSEcCtD
Arformoterol—Pruritus—Epirubicin—hematologic cancer	1.94e-05	5.93e-05	CcSEcCtD
Arformoterol—Dizziness—Methotrexate—hematologic cancer	1.94e-05	5.93e-05	CcSEcCtD
Arformoterol—Diarrhoea—Epirubicin—hematologic cancer	1.88e-05	5.74e-05	CcSEcCtD
Arformoterol—Hypersensitivity—Doxorubicin—hematologic cancer	1.87e-05	5.72e-05	CcSEcCtD
Arformoterol—Vomiting—Methotrexate—hematologic cancer	1.87e-05	5.7e-05	CcSEcCtD
Arformoterol—Rash—Methotrexate—hematologic cancer	1.85e-05	5.65e-05	CcSEcCtD
Arformoterol—Dermatitis—Methotrexate—hematologic cancer	1.85e-05	5.64e-05	CcSEcCtD
Arformoterol—Headache—Methotrexate—hematologic cancer	1.84e-05	5.61e-05	CcSEcCtD
Arformoterol—Asthenia—Doxorubicin—hematologic cancer	1.82e-05	5.57e-05	CcSEcCtD
Arformoterol—Dizziness—Epirubicin—hematologic cancer	1.82e-05	5.54e-05	CcSEcCtD
Arformoterol—Pruritus—Doxorubicin—hematologic cancer	1.8e-05	5.49e-05	CcSEcCtD
Arformoterol—Vomiting—Epirubicin—hematologic cancer	1.75e-05	5.33e-05	CcSEcCtD
Arformoterol—Nausea—Methotrexate—hematologic cancer	1.74e-05	5.32e-05	CcSEcCtD
Arformoterol—Diarrhoea—Doxorubicin—hematologic cancer	1.74e-05	5.31e-05	CcSEcCtD
Arformoterol—Rash—Epirubicin—hematologic cancer	1.73e-05	5.29e-05	CcSEcCtD
Arformoterol—Dermatitis—Epirubicin—hematologic cancer	1.73e-05	5.28e-05	CcSEcCtD
Arformoterol—Headache—Epirubicin—hematologic cancer	1.72e-05	5.25e-05	CcSEcCtD
Arformoterol—Dizziness—Doxorubicin—hematologic cancer	1.68e-05	5.13e-05	CcSEcCtD
Arformoterol—Nausea—Epirubicin—hematologic cancer	1.63e-05	4.98e-05	CcSEcCtD
Arformoterol—Vomiting—Doxorubicin—hematologic cancer	1.62e-05	4.93e-05	CcSEcCtD
Arformoterol—Rash—Doxorubicin—hematologic cancer	1.6e-05	4.89e-05	CcSEcCtD
Arformoterol—Dermatitis—Doxorubicin—hematologic cancer	1.6e-05	4.89e-05	CcSEcCtD
Arformoterol—Headache—Doxorubicin—hematologic cancer	1.59e-05	4.86e-05	CcSEcCtD
Arformoterol—Nausea—Doxorubicin—hematologic cancer	1.51e-05	4.61e-05	CcSEcCtD
Arformoterol—ADRB1—Signaling Pathways—CD86—hematologic cancer	7.9e-06	0.000187	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—NUP98—hematologic cancer	7.87e-06	0.000186	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—JAK2—hematologic cancer	7.86e-06	0.000186	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—HES1—hematologic cancer	7.79e-06	0.000184	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GSTT1—hematologic cancer	7.75e-06	0.000183	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—NCOR1—hematologic cancer	7.75e-06	0.000183	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CD86—hematologic cancer	7.73e-06	0.000183	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ADCY7—hematologic cancer	7.7e-06	0.000182	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—NCOA3—hematologic cancer	7.7e-06	0.000182	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—JAK2—hematologic cancer	7.69e-06	0.000182	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CSF2—hematologic cancer	7.66e-06	0.000181	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—FGF1—hematologic cancer	7.66e-06	0.000181	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—NUP214—hematologic cancer	7.65e-06	0.000181	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ADCY7—hematologic cancer	7.64e-06	0.000181	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—NCOA3—hematologic cancer	7.64e-06	0.000181	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	7.63e-06	0.00018	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—HES1—hematologic cancer	7.62e-06	0.00018	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—NUP214—hematologic cancer	7.58e-06	0.000179	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—NCOR1—hematologic cancer	7.58e-06	0.000179	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—SDC1—hematologic cancer	7.57e-06	0.000179	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—FOXO1—hematologic cancer	7.55e-06	0.000179	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—IL2—hematologic cancer	7.55e-06	0.000178	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PDGFRB—hematologic cancer	7.54e-06	0.000178	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	7.5e-06	0.000177	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—FGF1—hematologic cancer	7.5e-06	0.000177	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CSF2—hematologic cancer	7.5e-06	0.000177	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ABCG2—hematologic cancer	7.49e-06	0.000177	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—MTR—hematologic cancer	7.49e-06	0.000177	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—PIK3CB—hematologic cancer	7.46e-06	0.000176	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—MTR—hematologic cancer	7.43e-06	0.000176	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ABCG2—hematologic cancer	7.43e-06	0.000176	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PDGFRA—hematologic cancer	7.42e-06	0.000175	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—JAK1—hematologic cancer	7.4e-06	0.000175	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PRKCG—hematologic cancer	7.4e-06	0.000175	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—FOXO1—hematologic cancer	7.39e-06	0.000175	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—IL2—hematologic cancer	7.38e-06	0.000175	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PDGFRB—hematologic cancer	7.37e-06	0.000174	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ENO2—hematologic cancer	7.35e-06	0.000174	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—PIK3CB—hematologic cancer	7.3e-06	0.000173	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ENO2—hematologic cancer	7.29e-06	0.000172	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PDGFRA—hematologic cancer	7.26e-06	0.000172	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	7.24e-06	0.000171	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—JAK1—hematologic cancer	7.24e-06	0.000171	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PRKCG—hematologic cancer	7.24e-06	0.000171	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—MTHFR—hematologic cancer	7.16e-06	0.000169	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	7.14e-06	0.000169	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GSTT1—hematologic cancer	7.13e-06	0.000169	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GSTT1—hematologic cancer	7.07e-06	0.000167	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—SDC1—hematologic cancer	6.97e-06	0.000165	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	6.96e-06	0.000164	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—IL2RA—hematologic cancer	6.91e-06	0.000163	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—SDC1—hematologic cancer	6.91e-06	0.000163	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—IL2—hematologic cancer	6.86e-06	0.000162	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	6.83e-06	0.000162	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—TERT—hematologic cancer	6.83e-06	0.000161	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—IL2RA—hematologic cancer	6.76e-06	0.00016	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—IL2—hematologic cancer	6.71e-06	0.000159	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—TERT—hematologic cancer	6.68e-06	0.000158	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PDGFB—hematologic cancer	6.67e-06	0.000158	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	6.6e-06	0.000156	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PDGFB—hematologic cancer	6.52e-06	0.000154	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—TSC2—hematologic cancer	6.52e-06	0.000154	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	6.51e-06	0.000154	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CD44—hematologic cancer	6.44e-06	0.000152	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—NQO1—hematologic cancer	6.44e-06	0.000152	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—TSC2—hematologic cancer	6.37e-06	0.000151	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	6.31e-06	0.000149	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—FGFR3—hematologic cancer	6.27e-06	0.000148	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	6.23e-06	0.000147	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MAPK14—hematologic cancer	6.21e-06	0.000147	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—FGFR3—hematologic cancer	6.13e-06	0.000145	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CYCS—hematologic cancer	6.09e-06	0.000144	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—ESR1—hematologic cancer	6.09e-06	0.000144	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MAPK14—hematologic cancer	6.07e-06	0.000144	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—HSP90AA1—hematologic cancer	6.06e-06	0.000143	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—FN1—hematologic cancer	6.01e-06	0.000142	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PIK3CG—hematologic cancer	6.01e-06	0.000142	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—ESR1—hematologic cancer	5.95e-06	0.000141	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—BAD—hematologic cancer	5.94e-06	0.00014	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—NFKBIA—hematologic cancer	5.94e-06	0.00014	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—NQO1—hematologic cancer	5.92e-06	0.00014	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CD44—hematologic cancer	5.92e-06	0.00014	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—NOTCH1—hematologic cancer	5.88e-06	0.000139	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—FN1—hematologic cancer	5.88e-06	0.000139	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CD44—hematologic cancer	5.87e-06	0.000139	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—NQO1—hematologic cancer	5.87e-06	0.000139	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—BAD—hematologic cancer	5.81e-06	0.000137	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—NFKBIA—hematologic cancer	5.81e-06	0.000137	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CD80—hematologic cancer	5.76e-06	0.000136	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—NOTCH1—hematologic cancer	5.76e-06	0.000136	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—KIT—hematologic cancer	5.75e-06	0.000136	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PIK3CG—hematologic cancer	5.75e-06	0.000136	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—NRAS—hematologic cancer	5.75e-06	0.000136	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	5.75e-06	0.000136	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PTPN11—hematologic cancer	5.65e-06	0.000134	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CD80—hematologic cancer	5.64e-06	0.000133	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—KIT—hematologic cancer	5.63e-06	0.000133	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PIK3CG—hematologic cancer	5.63e-06	0.000133	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—NRAS—hematologic cancer	5.63e-06	0.000133	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CYCS—hematologic cancer	5.61e-06	0.000133	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—CREBBP—hematologic cancer	5.57e-06	0.000132	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	5.57e-06	0.000132	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CYCS—hematologic cancer	5.56e-06	0.000131	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PTPN11—hematologic cancer	5.53e-06	0.000131	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—HSP90AA1—hematologic cancer	5.52e-06	0.000131	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—MAPK3—hematologic cancer	5.51e-06	0.00013	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CREB1—hematologic cancer	5.48e-06	0.000129	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	5.45e-06	0.000129	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—BRAF—hematologic cancer	5.41e-06	0.000128	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—MAPK3—hematologic cancer	5.39e-06	0.000127	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GSTP1—hematologic cancer	5.37e-06	0.000127	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CCL2—hematologic cancer	5.36e-06	0.000127	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CREB1—hematologic cancer	5.36e-06	0.000127	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—IL6R—hematologic cancer	5.34e-06	0.000126	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CREBBP—hematologic cancer	5.34e-06	0.000126	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—BRAF—hematologic cancer	5.29e-06	0.000125	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PIK3CD—hematologic cancer	5.29e-06	0.000125	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CCL2—hematologic cancer	5.24e-06	0.000124	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—IL6R—hematologic cancer	5.23e-06	0.000124	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CREBBP—hematologic cancer	5.22e-06	0.000123	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—ALB—hematologic cancer	5.22e-06	0.000123	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	5.2e-06	0.000123	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MAP2K1—hematologic cancer	5.09e-06	0.00012	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—ABCB1—hematologic cancer	5.08e-06	0.00012	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PIK3CD—hematologic cancer	5.06e-06	0.00012	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—PIK3CA—hematologic cancer	5.01e-06	0.000118	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PIK3R1—hematologic cancer	4.99e-06	0.000118	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MAP2K1—hematologic cancer	4.98e-06	0.000118	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	4.97e-06	0.000117	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—KRAS—hematologic cancer	4.95e-06	0.000117	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PIK3CD—hematologic cancer	4.95e-06	0.000117	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GSTP1—hematologic cancer	4.94e-06	0.000117	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—NCOR1—hematologic cancer	4.94e-06	0.000117	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GSTM1—hematologic cancer	4.94e-06	0.000117	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—PIK3CA—hematologic cancer	4.9e-06	0.000116	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GSTP1—hematologic cancer	4.9e-06	0.000116	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—KRAS—hematologic cancer	4.84e-06	0.000115	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—FGF2—hematologic cancer	4.84e-06	0.000115	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PIK3R1—hematologic cancer	4.78e-06	0.000113	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	4.74e-06	0.000112	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—FGF2—hematologic cancer	4.74e-06	0.000112	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ABCB1—hematologic cancer	4.68e-06	0.000111	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PIK3R1—hematologic cancer	4.67e-06	0.00011	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—JAK2—hematologic cancer	4.64e-06	0.00011	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ABCB1—hematologic cancer	4.64e-06	0.00011	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PIK3CB—hematologic cancer	4.61e-06	0.000109	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—PIK3CA—hematologic cancer	4.55e-06	0.000108	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—JAK2—hematologic cancer	4.54e-06	0.000107	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—NCOR1—hematologic cancer	4.54e-06	0.000107	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GSTM1—hematologic cancer	4.54e-06	0.000107	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MDM2—hematologic cancer	4.53e-06	0.000107	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—NCOR1—hematologic cancer	4.5e-06	0.000106	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GSTM1—hematologic cancer	4.5e-06	0.000106	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—PIK3CA—hematologic cancer	4.45e-06	0.000105	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MDM2—hematologic cancer	4.43e-06	0.000105	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MTOR—hematologic cancer	4.41e-06	0.000104	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PIK3CB—hematologic cancer	4.41e-06	0.000104	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—MTHFR—hematologic cancer	4.36e-06	0.000103	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MTOR—hematologic cancer	4.31e-06	0.000102	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PIK3CB—hematologic cancer	4.31e-06	0.000102	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—HRAS—hematologic cancer	4.21e-06	9.95e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CDKN1B—hematologic cancer	4.14e-06	9.78e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—HRAS—hematologic cancer	4.12e-06	9.74e-05	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—AKT1—hematologic cancer	4.09e-06	9.68e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CASP3—hematologic cancer	4.06e-06	9.59e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—IL2—hematologic cancer	4.05e-06	9.57e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CDKN1B—hematologic cancer	4.05e-06	9.57e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—IL6—hematologic cancer	4.03e-06	9.53e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—MTHFR—hematologic cancer	4.01e-06	9.49e-05	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—AKT1—hematologic cancer	4e-06	9.47e-05	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PTEN—hematologic cancer	3.98e-06	9.41e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—MTHFR—hematologic cancer	3.98e-06	9.4e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CASP3—hematologic cancer	3.97e-06	9.38e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—IL2—hematologic cancer	3.96e-06	9.37e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CCND1—hematologic cancer	3.95e-06	9.33e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—IL6—hematologic cancer	3.94e-06	9.32e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—JUN—hematologic cancer	3.94e-06	9.31e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CCND1—hematologic cancer	3.86e-06	9.13e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—JUN—hematologic cancer	3.85e-06	9.11e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	3.84e-06	9.09e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CDKN1A—hematologic cancer	3.82e-06	9.03e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PTEN—hematologic cancer	3.81e-06	9.01e-05	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—EP300—hematologic cancer	3.8e-06	8.97e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CDKN1A—hematologic cancer	3.74e-06	8.83e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MAPK8—hematologic cancer	3.73e-06	8.81e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PTEN—hematologic cancer	3.73e-06	8.81e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—AKT1—hematologic cancer	3.72e-06	8.79e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PIK3CG—hematologic cancer	3.67e-06	8.67e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MAPK8—hematologic cancer	3.65e-06	8.62e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—AKT1—hematologic cancer	3.64e-06	8.6e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—EP300—hematologic cancer	3.63e-06	8.59e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—EP300—hematologic cancer	3.55e-06	8.4e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—SRC—hematologic cancer	3.53e-06	8.35e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	3.51e-06	8.29e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—SRC—hematologic cancer	3.46e-06	8.17e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—VEGFA—hematologic cancer	3.44e-06	8.14e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—STAT3—hematologic cancer	3.41e-06	8.06e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—NRAS—hematologic cancer	3.4e-06	8.04e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CREBBP—hematologic cancer	3.4e-06	8.03e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PIK3CG—hematologic cancer	3.37e-06	7.97e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—VEGFA—hematologic cancer	3.37e-06	7.96e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PIK3CG—hematologic cancer	3.34e-06	7.9e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—STAT3—hematologic cancer	3.33e-06	7.88e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—NRAS—hematologic cancer	3.33e-06	7.86e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MAPK3—hematologic cancer	3.26e-06	7.7e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PIK3CD—hematologic cancer	3.22e-06	7.62e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MAPK3—hematologic cancer	3.18e-06	7.53e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—ALB—hematologic cancer	3.18e-06	7.52e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MYC—hematologic cancer	3.17e-06	7.49e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—TGFB1—hematologic cancer	3.16e-06	7.47e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CREBBP—hematologic cancer	3.13e-06	7.39e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CREBBP—hematologic cancer	3.1e-06	7.33e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MYC—hematologic cancer	3.1e-06	7.32e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—TGFB1—hematologic cancer	3.09e-06	7.31e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PIK3R1—hematologic cancer	3.04e-06	7.19e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PIK3CD—hematologic cancer	2.96e-06	7.01e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PIK3CD—hematologic cancer	2.94e-06	6.95e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—KRAS—hematologic cancer	2.93e-06	6.92e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ALB—hematologic cancer	2.93e-06	6.92e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ALB—hematologic cancer	2.9e-06	6.86e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—KRAS—hematologic cancer	2.86e-06	6.77e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PIK3CB—hematologic cancer	2.81e-06	6.64e-05	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PIK3CA—hematologic cancer	2.81e-06	6.64e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PIK3R1—hematologic cancer	2.8e-06	6.62e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PIK3R1—hematologic cancer	2.77e-06	6.56e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PIK3CA—hematologic cancer	2.69e-06	6.35e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PIK3CA—hematologic cancer	2.63e-06	6.22e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—TP53—hematologic cancer	2.6e-06	6.15e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PIK3CB—hematologic cancer	2.58e-06	6.11e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PIK3CB—hematologic cancer	2.56e-06	6.05e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—TP53—hematologic cancer	2.54e-06	6.01e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—HRAS—hematologic cancer	2.49e-06	5.88e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—HRAS—hematologic cancer	2.43e-06	5.75e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PTEN—hematologic cancer	2.43e-06	5.74e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—IL6—hematologic cancer	2.38e-06	5.63e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—IL6—hematologic cancer	2.33e-06	5.5e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—EP300—hematologic cancer	2.31e-06	5.47e-05	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—AKT1—hematologic cancer	2.29e-06	5.42e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PTEN—hematologic cancer	2.23e-06	5.28e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PTEN—hematologic cancer	2.21e-06	5.23e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—AKT1—hematologic cancer	2.2e-06	5.19e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—AKT1—hematologic cancer	2.15e-06	5.08e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—EP300—hematologic cancer	2.13e-06	5.03e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—EP300—hematologic cancer	2.11e-06	4.99e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PIK3CA—hematologic cancer	1.71e-06	4.05e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PIK3CA—hematologic cancer	1.57e-06	3.72e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PIK3CA—hematologic cancer	1.56e-06	3.69e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—AKT1—hematologic cancer	1.4e-06	3.31e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—AKT1—hematologic cancer	1.29e-06	3.04e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—AKT1—hematologic cancer	1.28e-06	3.02e-05	CbGpPWpGaD
